Used with a reduced-calorie diet and more physical activity, it is approved to lower body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition. Like semaglutide it is a GLP-1 receptor agonist, but unlike the semaglutide tablets it can be taken with or without food.1
What it is
Orforglipron binds to and activates the GLP-1 receptor, the same target as semaglutide. The label says GLP-1 regulates appetite and calorie intake, that the drug decreases food intake, likely through lower appetite, and that it delays stomach emptying.1
The molecule is built very differently. Semaglutide is a modified copy of the GLP-1 hormone with a molecular weight of 4,113.58; orforglipron calcium has a molecular formula with 48 carbon atoms and a molecular weight of 902.0.1,2 That difference shows up in absorption. About 77% of a 0.8 mg dose of orforglipron reaches the blood, against 1% to 2% of an Ozempic or Wegovy tablet, and the label found no clinically relevant effect of food on it.1,3 It peaks 4 to 8 hours after a dose and has a half-life of about 29 to 49 hours, which suits once-daily dosing.1
How the dose climbs
The tablet is taken once a day, with or without food, swallowed whole. The label sets six steps, each held for at least 30 days.1
- Start at 0.8 mg a day.
- Then 2.5 mg, then 5.5 mg.
- If response and tolerability allow, 9 mg, 14.5 mg and at most 17.2 mg.
At that pace the first 17.2 mg tablet comes after at least 150 days. A missed tablet is taken as soon as possible, without doubling the next one; after 7 or more missed days in a row, the label says to restart the climb at a lower dose.1 Some medicines change the limits. Orforglipron is broken down mainly by the liver enzyme CYP3A4, so with a strong CYP3A4 inhibitor the maximum is 9 mg a day, and strong CYP3A4 inducers are to be avoided. The label tells people on birth control pills to switch to a non-oral method, or add a barrier method, for 30 days after starting and after each increase.1
What it did in trials
Two 72-week placebo-controlled trials support the approval. They used an investigational formulation, and the label reports them as the equivalent Foundayo doses of 5.5, 9 and 17.2 mg.1
Trial 1, ATTAIN-1, enrolled 3,127 adults without type 2 diabetes, who started at an average of about 102 to 104 kg. Weight fell by 7.4%, 8.3% and 11.1% on the three doses, against 2.1% on placebo. A loss of at least 15% was reached by 14.3%, 20.1% and 35.9%, against 6% on placebo.1
Trial 2, ATTAIN-2, enrolled 1,613 adults with type 2 diabetes.4 Weight fell by 5.1%, 7.0% and 9.6%, against 2.5% on placebo.1 For comparison, the Wegovy 25 mg tablet lowered weight by 13.6% at week 64 in its own trial, against 2.4% on placebo; the two drugs were not tested against each other.3
Side effects and warnings
In the pooled trials, nausea was reported by 26%, 34% and 35% on 5.5, 9 and 17.2 mg, against 10% on placebo. Constipation was reported by 20% to 27% against 9%, diarrhea by 21% to 25% against 11%, and vomiting by 13% to 24% against 4%.1 Our page on nausea on a GLP-1 covers what helps.
Foundayo carries the same boxed warning about thyroid C-cell tumors as the injectable GLP-1 medicines and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It is not to be combined with another GLP-1 receptor agonist.1
Foundayo in eight lines
| Fact | Foundayo |
|---|---|
| Active ingredient | Orforglipron |
| Maker | Eli Lilly |
| First U.S. approval | 2026 |
| Form | Tablet, once a day |
| Food | With or without |
| Doses | 0.8 mg to start, up to 17.2 mg |
| Half-life | About 29 to 49 hours |
| Approved for | Weight, in adults |
FOUNDAYO prescribing information, DailyMed version of August 13, 2026.1
Related terms
The other GLP-1 tablet for weight is the Wegovy tablet, which must be taken on an empty stomach with a little water and a 30-minute wait; our page on how to take the Wegovy pill explains why. Our page on GLP-1 costs without insurance lists self-pay prices.
Sources
- FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, U.S. National Library of Medicine, version published August 13, 2026; sections 1, 2, 4, 5, 6.1, 7, 8.3, 11, 12 and 14. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 11. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 12.3 and 14. accessdata.fda.gov
- ClinicalTrials.gov records NCT05869903 (ATTAIN-1) and NCT05872620 (ATTAIN-2), sponsor Eli Lilly and Company; read November 20, 2026. The label reports these trials by registry number. clinicaltrials.gov
Related analyses
How to take the Wegovy pill: the water, the 30-minute wait and the dose steps
Nausea on a GLP-1: how common, how long, when it peaks and what helps
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy vs Mounjaro: two drugs, two labels, and the trials that compared them
Log each Foundayo tablet and see your doses, weight and symptoms together.
Open Dose Insider